JP2008519769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519769A5 JP2008519769A5 JP2007540208A JP2007540208A JP2008519769A5 JP 2008519769 A5 JP2008519769 A5 JP 2008519769A5 JP 2007540208 A JP2007540208 A JP 2007540208A JP 2007540208 A JP2007540208 A JP 2007540208A JP 2008519769 A5 JP2008519769 A5 JP 2008519769A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein analog
- effective amount
- analog
- deamidated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 235000018102 proteins Nutrition 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 238000000034 method Methods 0.000 claims 11
- 108090000467 Interferon-beta Proteins 0.000 claims 8
- 238000011534 incubation Methods 0.000 claims 5
- 102100026720 Interferon beta Human genes 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- 229960001388 interferon-beta Drugs 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical group OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004811 liquid chromatography Methods 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- -1 cyclic imide Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 108091006028 deamidated proteins Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000012510 peptide mapping method Methods 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62683704P | 2004-11-10 | 2004-11-10 | |
| US60/626,837 | 2004-11-10 | ||
| PCT/US2005/040758 WO2006053134A2 (en) | 2004-11-10 | 2005-11-10 | Deamidated interferon-beta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008519769A JP2008519769A (ja) | 2008-06-12 |
| JP2008519769A5 true JP2008519769A5 (enExample) | 2008-11-13 |
| JP4891250B2 JP4891250B2 (ja) | 2012-03-07 |
Family
ID=36337216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540208A Expired - Fee Related JP4891250B2 (ja) | 2004-11-10 | 2005-11-10 | 脱アミドされたインターフェロンβ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7595040B2 (enExample) |
| EP (1) | EP1809662B1 (enExample) |
| JP (1) | JP4891250B2 (enExample) |
| KR (1) | KR101330626B1 (enExample) |
| CN (1) | CN101056890B (enExample) |
| AT (1) | ATE415421T1 (enExample) |
| AU (1) | AU2005304486B2 (enExample) |
| BR (1) | BRPI0517697A (enExample) |
| CA (1) | CA2587061C (enExample) |
| DE (1) | DE602005011321D1 (enExample) |
| ES (1) | ES2318575T3 (enExample) |
| MX (1) | MX2007004990A (enExample) |
| PL (1) | PL1809662T3 (enExample) |
| PT (1) | PT1809662E (enExample) |
| RU (1) | RU2404190C2 (enExample) |
| WO (1) | WO2006053134A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| EP2059528A2 (en) * | 2006-08-08 | 2009-05-20 | Novartis Ag | Recombinant interferon-beta with enhanced biological activity |
| WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| WO2009045553A1 (en) * | 2007-10-05 | 2009-04-09 | Barofold, Inc. | High pressure treatment of aggregated interferons |
| WO2015150468A2 (en) * | 2014-04-04 | 2015-10-08 | Ares Trading S.A. | Novel ifn beta protein analogs |
| RU2739261C1 (ru) * | 2019-12-31 | 2020-12-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ количественного определения антипролиферативной активности интерферона-бета человека |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| TR199901968T2 (xx) | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| CA2304808C (en) * | 1997-09-23 | 2011-03-22 | Michael Tschope | Liquid interferon-.beta. formulations |
| DE60045247D1 (de) | 1999-07-28 | 2010-12-30 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| RU2216345C1 (ru) * | 2002-03-21 | 2003-11-20 | Закрытое Акционерное Общество "Биокад" | Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием |
| KR100541850B1 (ko) * | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | 인간 인터페론-베타 변이체 및 그의 제조방법 |
-
2005
- 2005-11-10 AU AU2005304486A patent/AU2005304486B2/en not_active Ceased
- 2005-11-10 BR BRPI0517697-2A patent/BRPI0517697A/pt not_active IP Right Cessation
- 2005-11-10 EP EP05818235A patent/EP1809662B1/en not_active Expired - Lifetime
- 2005-11-10 WO PCT/US2005/040758 patent/WO2006053134A2/en not_active Ceased
- 2005-11-10 MX MX2007004990A patent/MX2007004990A/es active IP Right Grant
- 2005-11-10 RU RU2007121515/04A patent/RU2404190C2/ru not_active IP Right Cessation
- 2005-11-10 CA CA2587061A patent/CA2587061C/en not_active Expired - Fee Related
- 2005-11-10 AT AT05818235T patent/ATE415421T1/de active
- 2005-11-10 CN CN2005800381182A patent/CN101056890B/zh not_active Expired - Fee Related
- 2005-11-10 DE DE602005011321T patent/DE602005011321D1/de not_active Expired - Lifetime
- 2005-11-10 PT PT05818235T patent/PT1809662E/pt unknown
- 2005-11-10 JP JP2007540208A patent/JP4891250B2/ja not_active Expired - Fee Related
- 2005-11-10 PL PL05818235T patent/PL1809662T3/pl unknown
- 2005-11-10 ES ES05818235T patent/ES2318575T3/es not_active Expired - Lifetime
- 2005-11-10 US US11/271,516 patent/US7595040B2/en not_active Expired - Fee Related
- 2005-11-10 KR KR1020077011869A patent/KR101330626B1/ko not_active Expired - Fee Related
-
2009
- 2009-03-25 US US12/410,540 patent/US20090263355A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2310931T3 (es) | Analogos de interferon alfa humano de baja toxicidad. | |
| Thomas et al. | Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. | |
| JP3683291B2 (ja) | インターロイキン１２のｐ４０サブユニットを含んでなる医薬 | |
| JPH04506006A (ja) | ヒトサイトカイン、インターロイキン―９ | |
| DE3689870D1 (de) | Formulierung für rekombinantes beta-Interferon, Verfahren zur Gewinnung und Stabilisierung des beta-Interferons und dessen Verwendung. | |
| PL159182B1 (pl) | Sposób wytwarzania rekombinan towego bialka IL-6 PL PL PL PL PL PL | |
| IL94052A (en) | Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines | |
| IE58963B1 (en) | Y-ifn as active substance for inhibiting (preventing) degradation process in bone | |
| CA2100553A1 (en) | Treatment of neoplastic disease with interleukin-10 | |
| JPH01287039A (ja) | 正常細胞および癌細胞の増殖を抑制する方法 | |
| JP2008519769A5 (enExample) | ||
| CA2587061A1 (en) | Deamidated interferon-beta | |
| US20030175261A1 (en) | Pharmaceutical composition comrised of spider venoms, the production thereof , and its use for treating tumor diseases | |
| TW201522629A (zh) | 提供治療多肽之持續遞送的微器官及其使用方法 | |
| CN1168499C (zh) | 使粘液的粘度最佳化并且刺激肠功能的药物 | |
| US20110286966A1 (en) | Inhibitor of Endogenous Human Interferon-gamma | |
| JP2010500024A (ja) | 強化された生物学的活性を有する組換えインターフェロン−β | |
| US5726148A (en) | Method of treating metabolic bone diseases with an IL-1 receptor | |
| Richard et al. | Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo | |
| CN101039696A (zh) | 给药人il－18治疗创伤的方法 | |
| JPS6191135A (ja) | γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤 | |
| WO2003020752A1 (en) | A peptide and the pharmaceuticals containing it | |
| ES2208691T3 (es) | Modificacion gradual, superagonistas o antagonistas de proteinas y peptidos señal. | |
| RU2008125169A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а | |
| ElAttar et al. | Prostaglandin E2 antagonizes gingival fibroblast proliferation stimulated by interleukin-1β |